Imunon, Inc. 8-K

What Happened

• Imunon, Inc. announced a financing transaction with Streeterville Capital, LLC that closed June 3, 2026. The Company received $10.0 million in proceeds consisting of (i) sale of 250 shares of Series A Preferred Stock for $2.5 million, (ii) a Secured Promissory Note A-1 with original principal $2.72 million and (iii) a Secured Promissory Note B with original principal $5.0 million. The Securities Purchase Agreement was dated June 2, 2026; a Certificate of Designation for the Series A Preferred Stock was filed June 1, 2026, and a press release was issued June 4, 2026.

Key Details

• Total proceeds: $10,000,000; $5,000,000 of those proceeds were deposited into a subsidiary-controlled Cash Collateral Account as collateral for the Notes.
• Series A Preferred: 250 shares issued at $10,000 per share (aggregate $2.5M); Certificate designates up to 400 shares, each with a $12,000 stated value and an 8% annual preferred return payable in cash or additional preferred shares; not convertible into common stock.
• Notes: A-1 Note principal $2,720,000 at 8% per year; B Note principal $5,000,000 at 5% per year; both mature 18 months from closing; obligations are secured by substantially all company assets (excluding intellectual property) and guaranteed by certain subsidiaries.
• Other material terms: 7% placement agent fee on gross proceeds; 10% prepayment premium on principal prepayments; investor redemption rights begin six months after closing (up to $250,000 of A-1 principal per month) and additional redemption tied to certain trading-price/volume triggers; events of default allow acceleration, remedies against collateral, and increase note interest (to lesser of 15% or legal max).

Why It Matters

• This transaction materially changes Imunon’s short-term capital structure: it provides $10M in liquidity but creates secured debt obligations and preferred equity with cash-return obligations and collateral requirements.
• $5M held as cash collateral limits immediate use of half the proceeds until released (partially via specified note-exchange mechanics), affecting available cash for operations.
• Investors should note interest rates, maturity (18 months), prepayment penalties, redemption features, and the security and guarantee structure — all of which affect downside risk and potential cash flow priorities ahead of common shareholders.